Skip to content

Contrast enhanced Magnetic Resonance Imaging of the lungs in children with Cystic Fibrosis.

Contrast enhanced Magnetic Resonance Imaging of the lungs in children with Cystic Fibrosis. - Gd-MRI in CF.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON31207
Enrollment
30
Registered
2007-10-10
Start date
2007-12-12
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mucoviscoidosis

Interventions

None listed

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
2 Years to 17 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: signed informed consent, able to comply with protocol requirements, diagnosis of CF confirmed, age 6-18 years, stable condition, ability to perform lung function tests and breathhold manoeuvres, CT in the year before the MRI.

Exclusion criteria

Exclusion criteria: Exclusion criteria: inability to follow instructions of the investigator, current respiratory infection requiring IV antibiotics, pulmonary complications that might put patient at risk to participate , claustrophobia, history of anaphylactic reaction on contrast agent, any clinical condition which, according to the treating physician, might put patient at risk, severe asthma and/or severe allergies as determined by physician.

Design outcomes

Primary

MeasureTime frame
The ability of the radiologist and CF team to identify areas of the lung that are hypo perfused on the Gd-MRI relative to the proton-MRI. The distribution and volume of hypo perfused lung on the Gd-MRI will be compared to the distribution of trapped air on the proton-MRI and with the chest CT made in the previous year. After completion of the study all CTs and Gd-MRIs will be scored anonymous and in random order using a semi quantitative scoring system.

Secondary

MeasureTime frame
The ability of the radiologist and CF team to identify progression of peripheral bronchiectasis compared to the CT made in the previous year.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)